BioSpace News Archive

The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity

On December 21, 2020, Tekla Life Sciences Investors declared a special cash distribution of $0.02 per share in order to satisfy annual tax distribution requirements. The record date for the distribution is December 31, 2020 and the payable date is January 6, 2021. The Fund will trade ex-distribution on December 30, 2020. This distribution will be paid in cash and will

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is Reached

Omnicell, Inc., a leading provider of medication management solutions and adherence tools for health systems and pharmacies, announced that Kentucky-based Owensboro Health, a long-term sole source partner, will expand their medication management automation platform to central pharmacy operations with Omnicell’s Central Pharmacy Dispensing Service.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the pu

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimic

ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced it has donated one of its ReStore Exo-suits t

Atomwise, the leader in using artificial intelligence for small-molecule drug discovery, unveiled its growing portfolio of emerging joint venture companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders.

CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today a new initiative to deliver free medical ID bracelets to individuals in the United States living with Duchenne. With an initial limited quantity of 1,200 bracelets supplied by MyID, a leading provider of medical bracelets, they will be distributed on a first-come-first-serve basis. Ea

Acquisition expected to establish Peloton’s U.S. manufacturing footprint, enhance R&D capabilities, and accelerate growth of commercial verticals